duration of parenteral antibiotics was 3 days (range: 2 to 10).
Outcomes (10 studies).
LOS (5 studies)
LOS ranged from 3.5 to 11 days. The drop-outs rates ranged from 0 to 37%.
Six studies (458 patients) applied an early switch and early discharge strategy to an intervention and control group, and 5 studies provided standard deviations for LOS. The mean change in LOS was -1.64 days (95% confidence interval, CI: -3.30, 0.02, P=0.05); this did not differ significantly between intervention groups. Following the exclusion of 2 studies, which recommended an intervention LOS longer than or equal to the control LOS, the mean LOS was -3.04 days (95% CI: -4.90, -1.19).
2. Clinical outcomes. No significant differences were found between intervention groups for the following outcomes: complications of therapeutic failures (4 studies), mortality (3 studies), readmission (3 studies), health-related quality of life (3 studies), therapeutic success (2 studies), patient satisfaction with care (2 studies), intensive care unit admission (1 study), any adverse outcome (1 study), and relapse (1 study). No supporting data were presented.
3. Uncontrolled or historically-controlled studies (4 studies, 985 patients). Early switch strategies were applied to 710 (72%) of the patients in these studies. Where data were available, the mean time to switch and the mean LOS appeared less for patients receiving the intervention than for the control patients.
Authors' conclusions
There was considerable variation in the criteria used in studies of CAP for early switch from parenteral to oral antibiotics. Early switch and early discharge strategies may significantly and safely reduce the mean LOS when the recommended LOS is shorter than the actual LOS.
CRD commentary
The aims were stated and the inclusion criteria were defined in terms of the study design, participants, outcome and intervention; however, the emphasis appeared to have been on exclusion criteria. The criteria used to define patients with CAP were not specified, and the inclusion criteria for study design were broad. Several relevant databases were searched and attempts were made to locate unpublished material. By limiting the included studies to those published in English, it is possible that other relevant studies might have been omitted.
The methods used to select the primary studies were described and inter-rater agreement was assessed. Validity was not formally assessed or discussed. There was insufficient information on the primary studies, in particular: whether the prospective studies were randomised or non-randomised; the criteria used to diagnose CAP; characteristics of patients other than age; intervention, in terms of the specific drug and dose; definitions of criteria used for early switch or discharge; whether analysis was on an intention to treat basis; and side-effects.
Studies were pooled on the grounds that 'all patients were diagnosed as having CAP and the mean age is similar'. This was inappropriate since significant statistical heterogeneity was found. As the authors state, confounding factors such as death, complications, readmissions, intolerance of oral antibiotics and losses to follow-up, may have influenced the results. The discussion mentions the possibility that secular trends and geography may have contributed to the variation in LOS between studies.
The evidence supported the variation in LOS between studies, but there was insufficient evidence to support any other conclusions.
